What is the recommended management for methotrexate-induced neurotoxicity?

Methotrexate Neurotoxicity Management

For MTX-induced myelopathy, immediately discontinue methotrexate and consider intrathecal steroids along with high-dose folate metabolites (leucovorin), though evidence is limited; for aseptic meningitis, provide symptomatic treatment as it typically resolves spontaneously within 12-72 hours. 1

Clinical Presentation and Timing

MTX neurotoxicity manifests in distinct patterns based on route of administration and timing:

Intrathecal MTX Complications

Aseptic Meningitis (10-50% incidence)

• Develops within 2-4 hours after IT injection
• Symptoms: headache, nuchal stiffness, vomiting, fever, lethargy
• Duration: 12-72 hours (self-limited)
• CSF shows pleocytosis without bacterial infection features 1

Transverse Myelopathy (uncommon but severe)

• Occurs when high MTX levels persist in CSF ≥24 hours
• Presents with back/leg pain → paraparesis/paraplegia, sensory loss, sphincter dysfunction
• MRI: T2 hyperintensities in dorsal spinal cord columns
• Risk factors: concurrent craniospinal radiotherapy, frequent lumbar injections 1

High-Dose IV MTX Complications

Subacute neurotoxicity typically occurs 5-10 days after administration, particularly following two sequential cycles. Manifestations include seizures, confusion, encephalopathy, dysarthria, and choreiform movements 2. Brain MRI may show subcortical white matter diffusion-restricting lesions and T2-FLAIR hyperintensities 3.

Treatment Algorithm

For Myelopathy (Most Severe Form)

1. Immediately discontinue MTX 1
2. Intrathecal steroids: Inject slowly via lumbar route (evidence limited but recommended) 1
3. High-dose folate metabolites (leucovorin): Worth attempting despite limited data 1
4. Prognosis: Variable recovery; majority show clinical improvement 1

For Aseptic Meningitis

1. Symptomatic treatment only - condition is self-limited 1
2. CSF culture to exclude bacterial infection 1
3. Prevention for future doses: Consider concomitant IT dexamethasone 4 mg to prevent recurrence 1

For Subacute Encephalopathy/Seizures

Dextromethorphan (N-methyl-D-aspartate antagonist) shows promising results:

• Dose: 1-2 mg/kg orally
• Timing: Symptom resolution occurs within 1-2 days of initiation 3
• For secondary prevention: Give on day 0 (day of MTX) and day 7 4
• Evidence primarily from case series but demonstrates consistent efficacy 3, 2, 4

For Massive IT Overdose (>100 mg)

The FDA label and research support aggressive intervention 5, 6:

1. CSF drainage or exchange (most effective if performed immediately)
2. Ventriculolumbar perfusion
3. High-dose systemic leucovorin (IV, not IT - IT leucovorin toxicity is controversial)
4. Alkaline diuresis and intensive systemic support
5. Glucarpidase for toxic MTX concentrations with delayed clearance 5

Critical Prevention Strategies

Adequate Leucovorin Rescue

The timing and dose of folinic acid rescue is crucial and often underappreciated:

• Start leucovorin 24-36 hours after beginning high-dose MTX infusion
• Rescue started after 42 hours is associated with neurotoxicity 7
• Insufficient rescue is the primary cause of preventable neurotoxicity 7
• Standard dose: 15 mg orally every 6 hours for 10 doses starting 24 hours after MTX infusion 5

Risk Factor Monitoring

Higher risk patients include:

• Pediatric patients >10 years (7.44% incidence vs 3.13% in adults) 8
• Males (80.77% of cases) 8
• Patients receiving two sequential MTX cycles 2
• Those with renal impairment, concurrent radiotherapy 1

Common Pitfalls to Avoid

1. Do not delay leucovorin rescue beyond 36 hours - this is the most preventable cause of neurotoxicity 7
2. Do not administer leucovorin within 2 hours of glucarpidase if used for overdose 5
3. Do not assume normal MRI excludes neurotoxicity - 3 of 7 patients in one series had normal imaging but still had clinical neurotoxicity 2
4. Do not automatically discontinue MTX permanently - patients with normal MRI and resolved symptoms can often resume therapy safely 2
5. Monitor days 5-10 after high-dose MTX - this is the critical window for subacute toxicity 2

Long-Term Considerations

Patients experiencing acute MTX neurotoxicity demonstrate poorer long-term neurocognitive outcomes, particularly in fine motor function and attention (mean 4 years post-diagnosis), warranting early neuropsychological screening and intervention 9.